Xianbo Wang

List of Publications by Year
in descending order

52	1,279	777949	445137
papers	citations	13	33
		h-index	g-index

55	55	55	3011
all docs	docs citations	times ranked	citing authors

#	ARTICLE	IF	CITATIONS
1	Yindan Jiedu granules exhibit anti-inflammatory effect in patients with novel Coronavirus disease (COVID-19) by suppressing the NF-κB signaling pathway. Phytomedicine, 2022, 95, 153784.	2.3	13
2	Two-step fitness selection for intra-host variations in SARS-CoV-2. Cell Reports, 2022, 38, 110205.	2.9	38
3	Prevalence and clinical significance of serum sodium variability in patients with acute-on-chronic liver diseases: a prospective multicenter study in China. Hepatology International, 2022, 16, 183-194.	1.9	3
4	Neutrophil–lymphocyte ratio and the risk of 30-day mortality in patients with overt hepatic encephalopathy. European Journal of Gastroenterology and Hepatology, 2022, Publish Ahead of Print, .	0.8	2
5	Effects of Traditional Chinese Medicine Adjuvant Therapy on the Survival of Patients with Primary Liver Cancer. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-10.	0.5	3
6	Cohort profile: a multicentre prospective validation cohort of the Chinese Acute-on-Chronic Liver Failure (CATCH-LIFE) study. BMJ Open, 2021, 11, e037793.	0.8	20
7	Spontaneous Fungal Ascites Infection in Patients with Cirrhosis: An Analysis of 10 Cases. Infectious Diseases and Therapy, 2021, 10, 1033-1043.	1.8	6
8	Minimal Hepatic Encephalopathy and Biejia-Ruangan Are Associated with First Hospital Readmission in Nonalcoholic Cirrhosis Patients. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-9.	0.5	0
9	Neutrophil–lymphocyte ratio and the risk of hepatocellular carcinoma in patients with hepatitis B-caused cirrhosis. European Journal of Gastroenterology and Hepatology, 2021, 33, e686-e692.	0.8	11
10	Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway. Phytomedicine, 2021, 87, 153575.	2.3	41
11	Lower platelet counts were associated with 90-day adverse outcomes in acute-on-chronic liver disease patients. Annals of Palliative Medicine, 2021, 10, 9342-9353.	0.5	5
12	COVID-19 Cases from the First Local Outbreak of the SARS-CoV-2 B.1.1.7 Variant in China May Present More Serious Clinical Features: A Prospective, Comparative Cohort Study. Microbiology Spectrum, 2021, 9, e0027321.	1.2	8
13	Invasive Pulmonary Aspergillosis in Acute-on-Chronic Liver Failure Patients: Short-Term Outcomes and Antifungal Options. Infectious Diseases and Therapy, 2021, 10, 2525-2538.	1.8	3
14	CD200R Combined Neutrophil-Lymphocyte Ratio Predict 90-Day Mortality in HBV-Related Acute-On-Chronic Liver Failure. Frontiers in Medicine, 2021, 8, 762296.	1.2	4
15	Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance. Liver International, 2020, 40, 83-91.	1.9	14
16	Response to comments on: Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance. Liver International, 2020, 40, 730-730.	1.9	1
17	Adjuvant Fuzheng Huayu Capsule Reduces the Incidence of Hepatocellular Carcinoma in Patients with Hepatitis B-Caused Cirrhosis. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-9.	0.5	6
18	An Immunogram for an Individualized Assessment of the Antitumor Immune Response in Patients With Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 1189.	1.3	6

#	Article	IF	Citations
19	Comparison of Transcatheter Arterial Chemoembolization-Radiofrequency Ablation and Transcatheter Arterial Chemoembolization Alone for Advanced Hepatocellular Carcinoma with Macrovascular Invasion Using Propensity Score Analysis: A Retrospective Cohort Study. Journal of Oncology, 2020, 2020, 1-12.	0.6	4
20	Serum Clusterin: A Potential Marker for Assessing the Clinical Severity and Short-Term Prognosis of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure. Disease Markers, 2020, 2020, 1-11.	0.6	0
21	Use of a Novel Thyroid-Stimulating Hormone Model for Predicting the Progression of Hepatocellular Carcinoma . OncoTargets and Therapy, 2020, Volume 13, 11421-11431.	1.0	1
22	Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. Journal of Translational Medicine, 2020, 18, 206.	1.8	625
23	Differentiating Between 2019 Novel Coronavirus Pneumonia and Influenza Using a Nonspecific Laboratory Marker–Based Dynamic Nomogram. Open Forum Infectious Diseases, 2020, 7, ofaa169.	0.4	9
24	Machine learning-based development and validation of a scoring system for progression-free survival in liver cancer. Hepatology International, 2020, 14, 567-576.	1.9	19
25	SPARC Negatively Correlates With Prognosis After Transarterial Chemoembolization and Facilitates Proliferation and Metastasis of Hepatocellular Carcinoma via ERK/MMP Signaling Pathways. Frontiers in Oncology, 2020, 10, 813.	1.3	11
26	Artificial neural network-based models used for predicting 28- and 90-day mortality of patients with hepatitis B-associated acute-on-chronic liver failure. BMC Gastroenterology, 2020, 20, 75.	0.8	10
27	Nomogram for Individualized Prediction of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis on Conservative Treatment. BioMed Research International, 2020, 2020, 1-9.	0.9	1
28	Clinical features and outcomes of bacterascites in cirrhotic patients: A retrospective, multicentre study. Liver International, 2020, 40, 1447-1456.	1.9	11
29	Chlorogenic Acid Decreases Malignant Characteristics of Hepatocellular Carcinoma Cells by Inhibiting DNMT1 Expression. Frontiers in Pharmacology, 2020, 11, 867.	1.6	23
30	<i>Fufang Banmao</i> Capsule, a Traditional Chinese Medicinal Formulation, Enhances the Survival of Patients with Hepatocellular Carcinoma and Vp3–4 Portal Vein Tumor Thrombosis Undergoing Supportive Treatment. Journal of Alternative and Complementary Medicine, 2020, 26, 956-965.	2.1	9
31	Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019. Frontiers in Pharmacology, 2020, 11, 634266.	1.6	8
32	Protective Effect of Probiotics against Esophagogastric Variceal Rebleeding in Patients with Liver Cirrhosis after Endoscopic Therapy. Medical Science Monitor, 2020, 26, e924040.	0.5	5
33	Culture-Positive Spontaneous Ascitic Infection in Patients with Acute Decompensated Cirrhosis: Multidrug-Resistant Pathogens and Antibiotic Strategies. Yonsei Medical Journal, 2020, 61, 145.	0.9	11
34	Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Gut and Liver, 2020, 14, 232-247.	1.4	37
35	Comparative effectiveness and safety of traditional Chinese medicine supporting Qi and enriching blood for cancer related anemia in patients not receiving chemoradiotherapy: a meta-analysis and systematic review. Drug Design, Development and Therapy, 2019, Volume 13, 221-230.	2.0	19
36	Impact of gender as a prognostic factor in HBV-related Hepatocellular Carcinoma: the survival strength of female patients in BCLC stage 0-B. Journal of Cancer, 2019, 10, 4237-4244.	1.2	6

#	Article	IF	Citations
37	PD-1+ TIGIT+ CD8+ T cells are associated with pathogenesis and progression of patients with hepatitis B virus-related hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2019, 68, 2041-2054.	2.0	72
38	<p>Effects of various interventions on the occurrence of macrovascular invasion of hepatocellular carcinoma after the baseline serum &gamma;-glutamyltransferase stratification</p>. OncoTargets and Therapy, 2019, Volume 12, 1671-1679.	1.0	2
39	Nomogram prediction of individual prognosis of patients with acute-on-chronic hepatitis B liver failure. Digestive and Liver Disease, 2019, 51, 425-433.	0.4	17
40	A new scoring model predicting macroscopic vascular invasion of early-intermediate hepatocellular carcinoma. Medicine (United States), 2018, 97, e13536.	0.4	6
41	Effect of serum triglyceride level on the prognosis of patients with hepatocellular carcinoma in the absence of cirrhosis. Lipids in Health and Disease, 2018, 17, 248.	1.2	11
42	Development and external validation of a prognostic nomogram for acute decompensation of chronic hepatitis B cirrhosis. BMC Gastroenterology, 2018, 18, 179.	0.8	12
43	Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment. European Journal of Gastroenterology and Hepatology, 2018, 30, 1352-1360.	0.8	6
44	Nomogram prediction of individual prognosis of patients with hepatocellular carcinoma. BMC Cancer, 2017, 17, 91.	1.1	48
45	A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice. International Journal of Infectious Diseases, 2017, 62, 18-25.	1.5	8
46	Efficacy of Nucleot(s)ide Analogs Therapy in Patients with Unresectable HBV-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Disease Markers, 2017, 2017, 1-10.	0.6	6
47	HbA1c-Based Score Model for Predicting Death Risk in Patients with Hepatocellular Carcinoma and Type 2 Diabetes Mellitus. Journal of Diabetes Research, 2017, 2017, 1-7.	1.0	4
48	Association of neutrophil-lymphocyte ratio and T lymphocytes with the pathogenesis and progression of HBV-associated primary liver cancer. PLoS ONE, 2017, 12, e0170605.	1.1	21
49	Downregulation of serum RAB27B confers improved prognosis and is associated with hepatocellular carcinoma progression through PI3K-AKT-P21 signaling. Oncotarget, 2017, 8, 61118-61132.	0.8	10
50	Matrine induces the hepatic differentiation of WB-F344 rat hepatic progenitor cells and inhibits Jagged 1/HES1 signaling. Molecular Medicine Reports, 2016, 14, 3841-3847.	1.1	12
51	Galactose protects hepatocytes against TNF-α-induced apoptosis by promoting activation of the NF-κB signaling pathway in acute liver failure. Laboratory Investigation, 2015, 95, 504-514.	1.7	18
52	Imbalance between circulating CD4$^+$ regulatory T and conventional T lymphocytes in patients with HBVâ€related acuteâ€onâ€chronic liver failure. Liver International, 2013, 33, 1517-1526.	1.9	33